Ascletis Pharma (OTCMKTS:ASCLF – Get Free Report) is anticipated to post its results after the market closes on Monday, August 31st. Analysts expect the company to announce earnings of ($0.0294) per share and revenue of $4.0690 million for the quarter.
Ascletis Pharma Trading Down 3.0%
ASCLF opened at $1.30 on Friday. Ascletis Pharma has a 12-month low of $1.07 and a 12-month high of $2.50. The stock has a fifty day simple moving average of $1.32 and a two-hundred day simple moving average of $1.70.
About Ascletis Pharma
Ascletis Pharma (OTCMKTS:ASCLF) is a clinical‐stage biopharmaceutical company headquartered in Hangzhou, China, dedicated to the research, development and commercialization of therapies for viral and liver diseases. Since its founding in 2013, the company has built an integrated platform spanning small‐molecule discovery, process chemistry and clinical development. Ascletis is listed on the Hong Kong Stock Exchange and maintains facilities for both clinical research and commercial manufacturing in Mainland China.
The company’s core pipeline focuses on direct‐acting antiviral agents targeting hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).
Read More
- Five stocks we like better than Ascletis Pharma
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Ascletis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascletis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
